{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Momelotinib", "query": { "intervention": "Momelotinib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Momelotinib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T16:56:35.148Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07071155", "title": "Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndromes", "Myeloproliferative Overlap Neoplasms", "Chronic Neutrophilic Leukemia" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 18, "start_date": "2026-03-19", "completion_date": "2028-07-30", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07071155" }, { "nct_id": "NCT02124746", "title": "Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis", "Polycythemia Vera", "Essential Thrombocythemia" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2014-04-30", "completion_date": "2018-12-06", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Orange, California • Stanford, California + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02124746" }, { "nct_id": "NCT03441113", "title": "Extended Access of Momelotinib in Adults With Myelofibrosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Post-polycythemia Vera Myelofibrosis (Post-PV MF)", "Primary Myelofibrosis (PMF)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)", "Primary Myelofibrosis" ], "interventions": [ { "name": "MMB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2018-05-03", "completion_date": "2026-12-11", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Orange, California • Stanford, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03441113" }, { "nct_id": "NCT02206763", "title": "Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EGFR Mutated EGFR TKI Naive Metastatic NSCLC" ], "interventions": [ { "name": "Momelotinib (MMB)", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2014-10-16", "completion_date": "2017-02-16", "has_results": false, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 3, "location_summary": "Duarte, California • Palo Alto, California • Whittier, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206763" }, { "nct_id": "NCT02244489", "title": "Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Momelotinib (MMB)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-11-05", "completion_date": "2017-04-05", "has_results": false, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Nashville, Tennessee + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02244489" }, { "nct_id": "NCT05980806", "title": "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Moderate Thrombocytopenia", "Mild Thrombocytopenia" ], "interventions": [ { "name": "Selinexor 60 mg", "type": "DRUG" }, { "name": "Selinexor 40 mg", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Pacritinib", "type": "DRUG" }, { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2024-04-22", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 7, "location_summary": "Duarte, California • Columbia, Maryland • New York, New York + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Columbia", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05980806" }, { "nct_id": "NCT00935987", "title": "Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "CYT387", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2009-11", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 3, "location_summary": "Stanford, California • Boston, Massachusetts • Rochester, Minnesota", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00935987" }, { "nct_id": "NCT02258607", "title": "Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Momelotinib (MMB)", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-03-11", "completion_date": "2017-02-27", "has_results": false, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 5, "location_summary": "Duarte, California • Sacramento, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Fairfax", "state": "Virginia" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02258607" }, { "nct_id": "NCT01998828", "title": "Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycythemia Vera", "Essential Thrombocythemia" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2014-02-19", "completion_date": "2015-05-07", "has_results": false, "last_update_posted_date": "2020-04-20", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Whittier, California • Tupelo, Mississippi + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Whittier", "state": "California" }, { "city": "Tupelo", "state": "Mississippi" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998828" }, { "nct_id": "NCT06847867", "title": "A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-06-05", "completion_date": "2027-12-29", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-01T16:56:35.148Z", "location_count": 6, "location_summary": "Goodyear, Arizona • Duarte, California • Irvine, California + 3 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06847867" } ] }